Twitter | Search | |
Search Refresh
IBDJournal & CC360 Oct 7
Where should be positioned in the treatment algorithm for ? This will likely be an ongoing debate. This review gives a summary of available data and specific populations that may benefit from its use:
Reply Retweet Like
Naveen Pemmaraju, MD 10h
Outstanding primer video by Dr Ruben Mesa ⁦⁩ on FDA Approval of - 2nd in class - for intermediate to high-risk, selected patients with Myelofibrosis: Key Questions Addressed - ⁦⁩ |
Reply Retweet Like
Meg 5 Feb 18
Today I signed up for a clinical trial.
Reply Retweet Like
Follicle Thought.com (Hair Growth Research) Aug 15
It's an uncertain future for Aclaris' JAK inhibitor program. This comes about 2 months after the company announced positive results for AGA.
Reply Retweet Like
Tracy 11 Jan 12
AG490 and hepcidin-mediated diseases
Reply Retweet Like
Tracy 13 Dec 11
Adverse effects of ruxolitinib treatment discontinuation in MPNs
Reply Retweet Like
Tracy 7 Jan 12
Combination therapy of a pan-JAK inhibitor and a BCR-ABL inhibitor in CML
Reply Retweet Like
Xmaease 7 Jun 18
The latest The Natural Skincare Daily!
Reply Retweet Like
Michele B Kaufman 1 Mar 12
Reply Retweet Like
AlopeciaGone 17 Dec 17
Reply Retweet Like
Prescriber 3 Jan 18
Our article of the week investigates the future potential of JAK inhibitors to treat autoimmune disorders and cancers, and is available online at -
Reply Retweet Like
IBDJournal & CC360 Oct 19
Patients treated with for are at increased risk of also known as . Learn more about the risk, epidemiology, prevention and treatment of Zoster in this review:
Reply Retweet Like
IBDJournal & CC360 Oct 21
In patients treated with for , this study showed higher risk of associated with increased age, Asian descent, prior anti-TNF use, higher dose tofacitinib and use:
Reply Retweet Like
CBPartners 29 Mar 17
XELJANZ approved in the EU for the treatment of moderate-to-severe
Reply Retweet Like
Michele B Kaufman 7 Nov 12
Reply Retweet Like
Lisa Heidi 8 Jun 17
Reply Retweet Like
MPMI_UoM 21 Jul 17
Reply Retweet Like
SelectClinicalTrials 30 Jun 17
Reply Retweet Like
AndrogeneticAlopecia 23 Jun 16
Reply Retweet Like
1stOncology Dec 4
Updated Interim Results from Ongoing Phase 2a Study of ’ Oral / Continues to Demonstrate Clinical Responses in Heavily Pre-Treated
Reply Retweet Like